NEW YORK (GenomeWeb News) – Investment bank Piper Jaffray today downgraded Hologic amid anecdotal evidence suggesting Roche may be poised to take market share away from Hologic's sexually transmitted disease testing business.

Piper Jaffray lowered its rating for Bedford, Mass.-based Hologic to Neutral from Overweight and reduced the price target on its shares to $21 from $27.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.